Home Cart Sign in  
Chemical Structure| 572924-54-0 Chemical Structure| 572924-54-0

Structure of Ridaforolimus
CAS No.: 572924-54-0

Chemical Structure| 572924-54-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Treatment of HT-1080 cells with Deforolimus induces a dose-dependent inhibition of phosphorylation of both S6 and 4E-BP1, with IC50 of 0.2 nM and 5.6 nM, respectively, and leads to a decrease in cell size, an increase in the proportion of cells in the G1 phase of the cell cycle, and inhibition of glucose uptake.

Synonyms: Deforolimus; AP23573; Deforolimus, Ridaforolimus

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ridaforolimus

CAS No. :572924-54-0
Formula : C53H84NO14P
M.W : 990.21
SMILES Code : O=C(N1CCCC[C@]1(C(O[C@]([H])([C@@H](C[C@@H](C[C@H]2OC)CC[C@H]2OP(C)(C)=O)C)CC([C@H](C)/C=C(C)/[C@@H](O)[C@@H](OC)C([C@@H](C3)C)=O)=O)=O)[H])C([C@]([C@H](C)CC4)(O)O[C@@]4(C[C@H](OC)/C(C)=C/C=C/C=C/[C@H]3C)[H])=O
Synonyms :
Deforolimus; AP23573; Deforolimus, Ridaforolimus
MDL No. :MFCD13184816

Safety of Ridaforolimus

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Ridaforolimus

PI3K-AKT

Isoform Comparison

Biological Activity

Description
Ridaforolimus (MK-8669) is a potent and selective inhibitor of mTOR, effectively inhibiting ribosomal protein S6 phosphorylation with an IC50 of 0.2 nM in HT-1080 cells[1].
Target
  • mTOR

    mTOR, IC50:0.2 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
MG63 osteosarcoma cells 10 μM 3 days To evaluate the inhibitory effect of Ridaforolimus in combination with doxorubicin on osteosarcoma cells. Results showed that osteosarcoma cells in 3D environments were less sensitive to the combination therapy. PMC7027943
A549-ACE2 cells 20 μM 4 h To study the effect of Rapalogs on SARS-CoV-2 infection, it was found that Rapamycin, Everolimus, and Temsirolimus significantly enhanced infection, while Ridaforolimus had a lesser effect. PMC9753997
HeLa-ACE2 cells 20 μM 4 h To study the effect of Rapalogs on SARS-CoV-2 infection, it was found that Rapamycin, Everolimus, and Temsirolimus significantly enhanced infection, while Ridaforolimus had a lesser effect. PMC9753997

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Hamsters SARS-CoV-2 infection model Intraperitoneal injection 3 mg/kg Injected 4 hours before infection and again on day 2 post-infection To study the effect of Rapamycin and Ridaforolimus on SARS-CoV-2 infection, it was found that Rapamycin significantly increased viral replication and disease severity, while Ridaforolimus had a lesser effect. PMC9753997

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00112372 Cancer PHASE1 COMPLETED 2025-03-09 -
NCT01431534 Solid Tumors PHASE1 TERMINATED 2018-05-25 -
NCT00694083 Neoplasm PHASE1 COMPLETED 2009-09-06 -
NCT00087451 Malignant Glioma|Glioblastoma|... More >>Gliosarcoma Less << PHASE1 COMPLETED 2025-11-05 Center For Neuro-Oncology, Dan... More >>a Farber Cancer Institute, Boston, Massachusetts, 02115, United States|The Brain Tumor Center at Duke, Duke University Medical Center, Durham, North Carolina, 27710, United States|Brain Tumor Institute, The Cleveland Clinic, Cleveland, Ohio, 44195, United States|M.D. Anderson Cancer Center, Houston, Texas, 77030, United States Less <<
NCT01010672 Sarcoma PHASE2 COMPLETED 2025-01-13 -
NCT01212627 Non-Small Cell Lung Cancer PHASE1 TERMINATED 2025-04-13 memorial Hospital of Rhode isl... More >>and, Pawtucket, Rhode Island, 02860, United States|The Miriam Hospital, Providence, Rhode Island, 02906, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.01mL

0.20mL

0.10mL

5.05mL

1.01mL

0.50mL

10.10mL

2.02mL

1.01mL

References

 

Historical Records

Categories